基因治疗与年龄相关的黄斑退化
1Department of Ophthalmology, Harvard Medical School, Boston, MA.
International ophthalmology clinics
|July 2, 2025
概括
基因疗法为与年龄相关的黄斑退化 (AMD) 提供了新的希望. 本综述涵盖了药物输送,载体和正在进行的临床试验,用于湿和干 AMD,突出显示有前途的进展.
科学领域:
- 眼科医生 眼科 眼科
- 遗传学 是一个遗传学.
- 生物技术是生物技术.
背景情况:
- 与年龄相关的黄斑退化 (AMD) 是导致视力丧失的主要原因.
- 基因疗法为AMD提供了一个新的治疗途径.
- 最近的进展需要对目前的AMD基因治疗策略进行审查.
研究的目的:
- 审查与年龄相关的黄斑退化症 (AMD) 的基因疗法方法.
- 讨论药物管理方法,输送载体和正在进行的临床试验.
- 涵盖湿性和干性AMD的基因疗法应用.
主要方法:
- 关于AMD基因疗法的当前文献的综述.
- 药物管理路径的分析: 下, 内和 上.
- 对病毒 (腺病毒,晶病毒,AAV) 和非病毒 (LNP,基于聚合物) 载体的评估.
- 目前正在进行的临床试验对湿和干 AMD 的总结.
主要成果:
- 多种药物给药途径是可行的眼部基因疗法.
- 对于AMD基因疗法,正在探索各种病毒和非病毒载体.
- 一些临床试验正在积极调查湿性 (例如,ADVM-022,RGX-314) 和干性AMD (例如,GT-005,JNJ-1887) 的基因疗法.
结论:
- 基因疗法在治疗与年龄相关的黄斑退化方面具有显著的前景.
- 不同的传递系统和载体正在推进AMD治疗选择.
- 目前正在进行的临床试验对于验证这些新型疗法的有效性和安全性至关重要.
更多相关视频
07:04Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
Published on: February 4, 2021
2.1K
09:46Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy
Published on: February 26, 2021
3.3K
相关概念视频
iPS Cell Differentiation
2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
Gene Therapy
25.9K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.9K
